News & Updates
Filter by Specialty:
Insulin glargine, degludec yield comparable effects on glycaemic control
In patients with of type 2 diabetes (T2D), glargine 300 U/mL (Gla-300) and degludec 100 U/mL (Deg-100) deliver similar improvements in glycaemic control, without increasing weight and hypoglycaemic events over 6 months of treatment, according to data from the retrospective RESTORE-2 NAIVE study.
Insulin glargine, degludec yield comparable effects on glycaemic control
09 Sep 2022Semaglutide lowers stroke risk in type 2 diabetes with high CV risk
A post hoc analysis of the SUSTAIN 6 and PIONEER 6 trials has found that semaglutide reduces incidence of any stroke in people with type 2 diabetes (T2D) at high cardiovascular (CV) risk vs placebo.
Semaglutide lowers stroke risk in type 2 diabetes with high CV risk
09 Sep 2022Intravesical pembrolizumab delivers antitumour activity in NMIBC
A recent first-in-human study has shown that directly applying pembrolizumab to the bladder is a safe and effective treatment option for patients with nonmuscle-invasive bladder cancer (NMIBC) who are unresponsive to bacillus Calmette-Guérin (BCG) treatment.